Effects of tissue inhibitor of metalloproteinases on canine chondrocytes cultured in vitro with tumor necrosis factor-α

American Journal of Veterinary Research

Volumn 65, Issue 12, 2004, Pages 1611-1615

  Kuroki, Keiichi ^a   Cook, James L ^a   Kreeger, John M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; DNA; GLYCOSAMINOGLYCAN; HYDROXYPROLINE; NITRIC OXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFECT; EXTRACELLULAR MATRIX; HUMERUS HEAD; IN VITRO STUDY; LIQUID CULTURE; NONHUMAN;

ANIMALS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; DNA; DOGS; DRUG COMBINATIONS; GLYCOSAMINOGLYCANS; HYDROXYPROLINE; NITRIC OXIDE; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS;

EID: 11144263560     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.1611     Document Type: Article

References (45)

1. Smith RL. Degradative enzymes in osteoarthritis. Front Biosci 1999;4:D704-D712.
2. Nagase H, Woessner JF Jr. Role of endogenous proteinases in the degradation of cartilage matrix. In: Woessner JF Jr, Howell DS, eds. Joint cartilage degradation. New York: Marcel Dekker Inc, 1993;159-185.
3. Malemud CJ, Goldberg VM. Future directions for research and treatment of osteoarthritis. Front Biosci 1999;4:D762-D771.
4. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 2002;46:13-20.
5. Ray A, Kuroki K, Cook JL, et al. Induction of matrix metalloproteinase 1 gene expression is regulated by inflammation-responsive transcription factor SAF-1 in osteoarthritis. Arthritis Rheum 2003;48:134-145.
6. Hughes CE, Little CB, Buttner FH, et al. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem 1998;273:30576-30582.
7. Bonassar LJ, Sandy JD, Lark MW, et al. Inhibition of cartilage degradation and changes in physical properties induced by IL-1β and retinoic acid using matrix metalloproteinase inhibitors. Arch Biochem Biophys 1997;344:404-412.
8. Ellis AJ, Curry VA, Powell EK, et al. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 1994;201:94-101.
9. Kuroki K, Cook JL, Kreeger JM, et al. The effects of TIMP-1 and TIMP-2 on canine chondrocytes cultured in three-dimensional agarose culture system. Osteoarthritis Cartilage 2003;11:625-635.
10. Kashiwagi M, Tortorella M, Nagase H, et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001;276:12501-12504.
11. Hashimoto G, Aoki T, Nakamura H, et al. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, -2, -3 and -4). FEBS Lett 2001;494:192-195.
12. Schett G, Hayer S, Tohidast-Akrad M, et al. Adenovirus-based overexpression of tissue inhibitor of metalloproteinase 1 reduces tissue damage in the joints of tumor necrosis factor α transgenic mice. Arthritis Rheum 2001;44:2888-2898.
13. Apparailly F, Noel D, Millet V, et al. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum 2001;44:1444-1454.
14. Horton WE Jr, Udo I, Precht P, et al. Cytokine inducible matrix metalloproteinase expression in immortalized rat chondrocytes is independent of nitric oxide stimulation. In Vitro Cell Dev Biol Amin 1998;34:378-384.
15. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:585-594.
16. Chandrasekhar S, Harvey AK, Higginbotham JD, et al. Interleukin-1-induced suppression of type II collagen gene transcription involves DNA regulatory elements. Exp Cell Res 1990; 191:105-114.
17. Goldring MB, Birkhead J, Sandell LJ, et al. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988;82:2026-2037.
18. Taskiran D, Stefanovic-Racic M, Georgescu H, et al. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-148.
19. van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-172.
20. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:3127-3131.
21. Westacott CI, Atkins RM, Dieppe PA, et al. Tumor necrosis factor-alpha receptor expression on chondrocytes isolated from human articular cartilage. J Rheumatol 1994;21:1710-1715.
22. Vuolteenaho K, Moilanen T, Hamalainen M, et al. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002;10:327-332.
23. Cook JL, Kreeger JM, Payne JT, et al. Three-dimensional culture of canine articular chondrocytes on multiple transplantable substrates. Am J Vet Res 1997;58:419-424.
24. Anderson CC, Cook JL, Kreeger JM, et al. In vitro effects of glucosamine and acetylsalicylate on canine chondrocytes in three-dimensional culture. Am J Vet Res 1999;60:1546-1551.
25. Cook JL, Anderson CC, Kreeger JM, et al. Effects of human recombinant interleukin-1β on canine articular chondrocytes in three-dimensional culture. Am J Vet Res 2000;61:766-770.
26. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylinethylene blue. Biochim Biophys Acta 1986;883:173-177.
27. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29:225-229.
28. Natarajan N, Shambaugh GE III, Elseth KM, et al. Adaptation of the diphenylamine (DPA) assay to a 96-well plate tissue culture format and comparison with the MTT assay. Biotechniques 1994; 17:166-171.
29. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126:131-138.
30. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-549.
31. Little CB, Flannery CR, Hughes CE, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999;344:61-68.
32. Tortorella MD, Malfait AM, Deccico C, et al. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9:539-552.
33. Malfait AM, Liu RQ, Ijiri K, et al. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002;277:22201-22208.
34. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-247.
35. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-1314.
36. Joosten LA, Helsen MM, Saxne T, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-5055.
37. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565-2570.
38. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158.
39. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-324.
40. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997;99:1231-1237.
41. Palmer RM, Hickery MS, Charles IG, et al. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993;193:398-405.
42. Goodstone NJ, Hardingham TE. Tumour necrosis factor alpha stimulates nitric oxide production more potently than interleukin-1beta in porcine articular chondrocytes. Rheumatology (Oxford) 2002;41:883-891.
43. Stefanovic-Racic M, Morales TI, Taskiran D, et al. The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. J Immunol 1996;156:1213-1220.
44. Oh M, Fukuda K, Asada S, et al. Concurrent generation of nitric oxide and superoxide inhibits proteoglycan synthesis in bovine articular chondrocytes: involvement of peroxynitrite. J Rheumatol 1998;25:2169-2174.
45. Studer R, Jaffurs D, Stefanovic-Racic M, et al. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 1999;7:377-379.